학술논문

Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC): Primary endpoint and subgroup analysis of the CEBIFOX trial
Document Type
Journal
Source
JOURNAL OF CLINICAL ONCOLOGY; MAY 20 2015, 33 15, 1p. Supplement: S
Subject
Language
English
ISSN
15277755